ESR1 and breast cancer: Triple-negative breast cancer (TNBC) is defined as ER/P- negative and HER2-negative and accounts for 10–15% BC [1], and the therapeutic options for this subtype are limited to chemotherapy with or without the addition of checkpoint inhibitor therapy and, in certain cases, PARP inhibitors.